European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromesRobert Knobler, Thomas Krieg, Veli‐Matti Kähäri et al.|Journal of the European Academy of Dermatology and Venereology|2017Cited by 261
OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper ResponseC. Jacquemin, Patrick Blanco, Nathalie Schmitt et al.|Immunity|2015Cited by 223
Platelet CD154 Potentiates Interferon-α Secretion by Plasmacytoid Dendritic Cells in Systemic Lupus ErythematosusP. Duffau, Patrick Blanco, Julien Sénéschal et al.|Science Translational Medicine|2010Cited by 219
Vitiligo-like lesions occurring in patients receiving anti-programmed cell death–1 therapies are clinically and biologically distinct from vitiligoM. Larsabal, Julien Sénéschal, A. Marti et al.|Journal of the American Academy of Dermatology|2017Cited by 157
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse eventsMarie Kostine, Thierry Schaeverbeke, Eleonora Mauric et al.|European Journal of Cancer|2021Cited by 93